International
Brasil 
Chile 
Deutschland 
España 
France 
Italia 
Panamá 
Portugal 
Russia 
UK 
A new alternative treatment in which growth factor rich plasma injections facilitate the restoration of ovarian function.
IVI Regenerate Ovary treatment consists of the administration of a small amount of enriched plasma in each ovary in a procedure similar to the puncture of oocytes. It is an outpatient treatment and the patient can return home after a brief observation period.
Growth factor rich plasma (GRP) is a novel technology that has meant significant clinical progress in the medical field and is starting to be used as an alternative for treating cases of premature ovarian insufficiency and diminished ovarian reserve. The technology is based on the principles of regenerative medicine, the purpose of which is to restore “the biological environment,” imitating and accelerating the body’s own regeneration processes.
Based on published studies, we have observed that in 2-3 months we can have some indication of whether the IVI Regenera Ovario treatment will be effective for the patient. We are always aware that we will not see a dramatic increase in ovarian reserve, but enough to be able to choose IVF treatment or obtain a greater number of eggs, which is crucial for women with poor response.
There is still no conclusive data, but we think that this treatment could be indicated in women with diminished ovarian reserve. At the same time, each case must be studied individually.
The information we have today is inconclusive in terms of ovarian quality. We have to keep in mind that, starting at 38, there is a significant increase in the number of embryos with chromosomal anomalies and this does not change with these procedures. However, in patients who respond to this treatment, there is an increase in the number of oocytes obtained.
It is one more step in increasing ovarian reserve which diminishes significantly with advancing age. But we still have a long road ahead of us. In any case, IVA is working on new ovarian rejuvenation technologies and is a pioneer in implementing many of them.
There are patients for whom one treatment is enough. Others receive two treatments. If we don’t achieve results with two, we choose another type of treatment.
